Motherboard vendors see shipments drop in 1Q17 despite new AMD, Intel processors
Monica Chen, Taipei; Joseph Tsai, DIGITIMES [Thursday 23 March 2017]
Despite Intel, AMD and Nvidia having all launched new processor or graphics chip products for the first quarter, motherboard players continue to suffer decreased shipments in the quarter and demand is also unlikely to pick up in the second, according to sources from the upstream supply chain.
Intel released several Kaby Lake-based processors and 200 series chipsets including the Z270 in January. AMD's 8-core Ryzen 7 1800X, 1700X and 1700 were launched in early March and Nvidia's GeForce GTX 1080 Ti also hit store shelves in March.
Intel also cut the prices for several of its previous-generation processors including Core i7-6950X and G328. Nvidia's GTX 1080 graphics cards also saw pricing drop from US$699 to US$499.
Because of weak graphics card demand especially from China, players have already started cutting prices for their GTX 1060 (starting US$249) and GTX 1070 (starting US$379) graphics card to stimulate demand.
Asustek Computer and Gigabyte Technology are expected to ship less than four million motherboards each in the first quarter, the lowest quarterly record in the past few years, while second- to third-tier players are expected to have even worse performances.
Although AMD has already prepared new Ryzen 5 series processors, Polaris-based RX500 series GPUs and next-generation Vega series GPUs for the second quarter, the sources believe these products are unlikely to have a significantly contribution overall because AMD only has a limited market share currently.
The sources pointed out that motherboard/graphics card players' overall shipments and revenues will see significant drops in the first half, but Asustek and Gigabyte are expected to see declines not as steep as the market's average thanks to demand from the gaming market.
But the sources expect demand from the PC DIY market to have a good chance to rise in the third quarter due to seasonality, as well as Intel's launch of its top-end Skylake-X and Kaby Lake-X processors and X299 chipsets, and AMD's release of its Ryzen 3 series processors for inexpensive mainstream sector and mass shipments of its Vega series GPUs, .
Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- CHL -2.7%, ACN -2.6%, KDMN -2.4%, CAG -1.9%, ASND -1.5%, BGNE -0.6%, EHIC -0.5%
Other news:
- TNDM -22.6% (prices offering of 18 mln shares at $1.25/share)
- HTBX -20.4% (prices underwritten public offering of 5 mln shares of its common stock at $0.80/share)
- QUIK -12.2% (prices 10 mln common stock offering at $1.50/share)
- OEC -8.3% (announces that Kinove Luxembourg Holdings and certain other sellers intend to offer an aggregate of 5 mln common shares in an underwritten public offering)
- RARE -6.9% (announces topline data from the Phase 2 study of UX007 in glucose transporter type-1 deficiency syndrome patients with seizures; study did not meet the primary endpoint)
- VNCE -5.3% (following late move higher)
- BLCM -4.3% (commences an underwritten public offering of 5,000,000 shares of its common stock)
- SHLD -3.9% (continued weakness)
- CHMI -3.8% (commences 4.5 mln common stock offering)
- ENPH -3.2% (files for approx 12 mln share common stock offering by selling shareholder)
- MMSI -3% (prices offering of 4.5 mln shares of common stock at $28.25 per share)
- KEYS -1.6% (offering of 11,428,571 common shares at $35.00 per share)
- MYL -0.9% ( indicated lower in after hours on EpiPen recall news)
Analyst comments:
- WLL -1.7% (downgraded to Sell from Neutral at UBS)
- GPOR -1.6% (downgraded to Neutral from Buy at Goldman)
- DG -1.2% (downgraded to Underperform from Neutral at Credit Suisse)
- NSC -1.1% (downgraded to Underperform at RBC Capital Mkts)
- MO -1.1% (downgraded to Underperform at RBC Capital Mkts)
- PEGI -1% (downgraded to Neutral from Outperform at Macquarie)
Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- TAT +9.6%, CGIX +8.6%, CMC +8.3%, PVH +7.3%, FIVE +6.7%, MLHR+5.6% APOP +4.4%, PIRS +2%, CUR +1.9%, CEO +1.4%, NEOT +1.4%
M&A news:
- ZNH +1.1% (issues statement, says it requested the halt pending the release of an announcement in relation to the possible major strategic cooperation which is the inside information of the Company)
Other news:
- HTGM +56.5% (obtains CE marking in the European Union for its HTG EdgeSeq ALKPlus Assay EU)
- DRWI +29.3% (announced the selection of the Harmony Enhanced MC backhaul solution by Corridor Communication )
- SSH +20.6% (highlights 'progress in successfully executing its Aquadex growth strategy')
- BEBE +7.5% ( says exploring strategic alternatives)
- DHT +6% (acquires 11 VLCCs from BW Group for $538 mln; will issue $256 million of DHT capital stock)
- INSY +5.8% (DEA has issued an interim final rule that would result in Syndros being placed in Schedule II of the Controlled Substances Act; anticipates finalizing the labeling and subsequent launch of Syndros in the second half of 2017)
- EGLT +5.6% (announces the issuance of new U.S. and international patents for its proprietary Guardian Technology)
- PRKR +4.8% ( seeing continued strength in afterhours - confirms will report financial results on Thursday, March 30, 2017 with call at 4:30 p.m. Eastern time)
- PENN +4.4% (will replace Cynosure in the S&P SmallCap 600)
- LJPC +1.9% (prices an underwritten public offering of approx 3.7 mln shares of common stock at $33.50/share for gross proceeds of $125 mln)
- CPB +1% (announces $1.5 bln share repurchase program)
Analyst comments:
- FEYE +8.4% (upgraded to Buy from Sell at Goldman)
- SVU +6.9% (upgraded to Outperform at RBC Capital Mkts)
- RACE +2.3% (upgraded to Buy from Neutral at Citigroup)
- CHK +2% (initiated with Buy at Stifel )
- KR +1.7% (upgraded to Outperform at RBC Capital Mkts)
- BABA +0.9% (initiated with Overweight ratings at Pacific Crest)
- JD +0.9% (initiated with Overweight ratings at Pacific Crest)